128 related articles for article (PubMed ID: 12188892)
1. Structure-based design of novel anticancer agents.
Uckun FM; Sudbeck EA; Mao C; Ghosh S; Liu XP; Vassilev AO; Navara CS; Narla RK
Curr Cancer Drug Targets; 2001 May; 1(1):59-71. PubMed ID: 12188892
[TBL] [Abstract][Full Text] [Related]
2. SPIKET and COBRA compounds as novel tubulin modulators with potent anticancer activity.
Uckun FM; Mao C; Jan ST; Huang H; Vassilev AO; Sudbeck EA; Navara CS; Narla RK
Curr Opin Investig Drugs; 2000 Oct; 1(2):252-6. PubMed ID: 11249582
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed anti-mitotic agents with pro-apoptotic activity.
Uckun FM
Curr Pharm Des; 2001 Nov; 7(16):1627-39. PubMed ID: 11562303
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
5. Spongistatins as tubulin targeting agents.
Uckun FM; Mao C; Jan ST; Huang H; Vassilev AO; Navara CS; Narla RK
Curr Pharm Des; 2001 Sep; 7(13):1291-6. PubMed ID: 11472268
[TBL] [Abstract][Full Text] [Related]
6. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of a novel synthetic spiroketal pyran as a pharmacophore for the marine natural product spongistatin 1.
Uckun FM; Mao C; Vassilev AO; Huang H; Jan ST
Bioorg Med Chem Lett; 2000 Mar; 10(6):541-5. PubMed ID: 10741549
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
[TBL] [Abstract][Full Text] [Related]
9. COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerizing activity as a novel anticancer agent.
Jan ST; Mao C; Vassilev AO; Navara CS; Uckun FM
Bioorg Med Chem Lett; 2000 Jun; 10(11):1193-7. PubMed ID: 10866379
[TBL] [Abstract][Full Text] [Related]
10. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
[TBL] [Abstract][Full Text] [Related]
11. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Uckun F; Dibirdik I; Sarkissian A; Qazi S
Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
[TBL] [Abstract][Full Text] [Related]
13. Tubulin-perturbing naphthoquinone spiroketals.
Balachandran R; Hopkins TD; Thomas CA; Wipf P; Day BW
Chem Biol Drug Des; 2008 Feb; 71(2):117-24. PubMed ID: 18194192
[TBL] [Abstract][Full Text] [Related]
14. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic nanoparticle constructs of a JAK3 tyrosine kinase inhibitor against human B-lineage ALL cells.
Uckun FM; Dibirdik I; Qazi S; Yiv S
Arzneimittelforschung; 2010; 60(4):210-7. PubMed ID: 20486472
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).
Narla RK; Liu XP; Klis D; Uckun FM
Clin Cancer Res; 1998 Oct; 4(10):2463-71. PubMed ID: 9796979
[TBL] [Abstract][Full Text] [Related]
17. EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
[TBL] [Abstract][Full Text] [Related]
18. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of a spongistatin AB-spiroketal analogue.
Smith AB; Corbett RM; Pettit GR; Chapuis JC; Schmidt JM; Hamel E; Jung MK
Bioorg Med Chem Lett; 2002 Aug; 12(15):2039-42. PubMed ID: 12113837
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.
Mu F; Coffing SL; Riese DJ; Geahlen RL; Verdier-Pinard P; Hamel TE; Johnson J; Cushman M
J Med Chem; 2001 Feb; 44(3):441-52. PubMed ID: 11462983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
